CAR-T Drugs Break Ground For Stem Cell Therapies In CNS, Says Brainstorm CEO
Brainstorm’s president and CEO Chaim Lebovits talks to Scrip about the company’s progress with personalized stem cell therapy NurOwn in ALS and what the future holds for cell therapy options in neurology.
You may also be interested in...
Pfizer is abandoning research to find new drugs for Alzheimer’s and Parkinson’s disease, realizing that finding treatments for the diseases is very tough - but M&A could allow an eventual return, analysts say.
Dendreon said late on 9 November that it has reached an agreement with certain holders of its convertible senior notes due in 2016 to seek Chapter 11 bankruptcy so that it can reorganize, sell the company or dispose of its assets to manage $620m in debt that must be repaid in 14 months.
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.